NCT00441870 - Study of EC0225 for the Treatment of Refractory or Metastatic Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Cancer

Interventions

DRUG

EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)

Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)

DRUG

99mTC-EC20 (Folic acid-technetium 99m conjugate)

20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging

Trial Locations (3)

21201

Greenebaum Cancer Center - University of Maryland Medicine, Baltimore

48201

Barbara Ann Karmanos Cancer Institute, Detroit

89135

Nevada Cancer Institute, Las Vegas